The design and biological properties of potent and selective inhibitors of protein kinase C.
Nixon
J S
JS
Research Centre, Roche Products Ltd, Welwyn Garden City, Herts, U.K.
Bishop
J
J
Bradshaw
D
D
Davis
P D
PD
Hill
C H
CH
Elliott
L H
LH
Kumar
H
H
Lawton
G
G
Lewis
E J
EJ
Mulqueen
M
M
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D002227:Carbazoles / Q000494:pharmacology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology; D007249:Inflammation / Q000188:drug therapy; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007546:Isoquinolines / Q000494:pharmacology; D008301:Maleimides / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D015394:Molecular Structure; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015290:Second Messenger Systems; D015398:Signal Transduction; D013449:Sulfonamides / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002227:Carbazoles; D004791:Enzyme Inhibitors; D007211:Indoles; D007527:Isoenzymes; D007546:Isoquinolines; D008301:Maleimides; D013449:Sulfonamides; C076005:Ro 31-8830; D011493:Protein Kinase C